Hillstar Bio Launches with $67 Million Series A Financing to Develop Next Wave of Precision Immunotherapies to Transform Autoimmune Treatment
Proceeds to fund advancement of the company’s lead TRBV9 program through clinical proof-of-concept study in axial spondyloarthritis and progression of broader pipeline Company’s approach selectively targets and depletes pathogenic immune cells with the potential to…